Friday, May 19, 2017 10:28:05 AM
Tetra Bio-Pharma Inc. (CSE: C.TBP, OTCQB: GRPOF, Forum) said Thursday it has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.
The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by IMS Institute for Healthcare Informatics.
The Ontario-based company was in the news recently when it and and Aphria Inc. (TSX: V.APH, OTCQB: APHQF, Forum) announced plans for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Tetra and Aphria will enter into a joint supply agreement, the companies said in a press release.
Read more at http://www.stockhouse.com/news/newswire/2017/05/18/tetra-bio-pharma-files-patent-for-treatment-cancer-ocular-disease#v5bq4J20Y5Hzv1ck.99
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM